A METHOD of using amobarbital sodium (Amytal Sodium) to study alterations in brain function has been described in previous papers. It has been noted that under the effect of this drug patterns of denial of illness1 and disorientation for time, place, and person2 could be reproduced in patients with brain disease after these phenomena were no longer present clinically.
In an effort to determine the value of amobarbital for diagnostic purposes a standardized procedure of interviewing was developed.3 In comparing the changes in behavior under amobarbital sodium of a group of 88 patients with brain disease and 50 normal * control patients, it was found that the presence of certain patterns of denial of illness and disorientation could differentiate the two groups empirically. Altogether, 57, or 65%, of the patients with brain disease showed behavioral changes not found in any of the control group.
It was noted that
WEINSTEIN EA, KAHN RL, SUGARMAN LA, MALITZ S. SERIAL ADMINISTRATION OF THE "AMYTAL TEST" FOR BRAIN DISEASE: Its Diagnostic and Prognostic Value. AMA Arch NeurPsych. 1954;71(2):217–226. doi:https://doi.org/10.1001/archneurpsyc.1954.02320380083010
Customize your JAMA Network experience by selecting one or more topics from the list below.